Ranolazine in Diastolic Heart Failure (RALI-DHF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01163734|
Recruitment Status : Completed
First Posted : July 16, 2010
Last Update Posted : July 12, 2012
|Condition or disease||Intervention/treatment||Phase|
|Diastolic Heart Failure||Drug: Ranolazine Other: Saline 0.9% and placebo tablet||Phase 2|
This is a randomized, double-blind, placebo-controlled proof-of-concept study of ranolazine in patients with heart failure with preserved ejection fraction (HFpEF). Patients will be randomized to receive ranolazine or placebo in a 1.5:1 ratio (12 ranolazine: 8 placebo).
Treatment will consist of intravenous infusion of study drug followed by oral treatment for a total of 14 days treatment period. Study contact will be made approximately 14 days after the treatment period to assess safety.
Cardiac catheterization will be performed for LV pressures and hemodynamic measurements before and after drug administration. Doppler ECHO, CPET, and NT-pro-BNP determination will be performed at screening and at end of study. Adverse events and safety labs will be monitored and collected.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Intravenous treatment followed oral treatment for 13 days.
Other Name: Ranexa
Placebo Comparator: Saline 0.9%
Saline 0.9% and placebo tablet
Other: Saline 0.9% and placebo tablet
Intravenous treatment followed by oral treatment for 13 days
Other Name: Normal Saline
- Change from baseline to 30 minutes in cardiac catheterization hemodynamic parameters at both resting and paced conditions [ Time Frame: Baseline to 30 minutes ]
Change from baseline to 30 minutes from initiation of study drug bolus No.1 in cardiac catheterization hemodynamic parameters at both resting and paced conditions:
Time-constant of relaxation (tau)
Left ventricular end-diastolic pressure (LVEDP)
dP/dtmin (minimal rate of LV pressure change)
- Change from baseline to Day 14 in mitral E wave velocity/mitral annular velocity (E/E') ratio [ Time Frame: Baseline to Day 14 ]
- Change from baseline to Day 14 in VO2 max [ Time Frame: Baseline to Day 14 ]
- Change from baseline to Day 14 in N-terminal pro-brain B-type natriuretic peptide (NT-pro-BNP) [ Time Frame: Baseline to Day 14 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01163734
|University Medicine Goettingen (UMG)|
|Principal Investigator:||Lars S. Maier, MD||University Medicine Göttingen, Cardiac Center|